We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+19.28%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$8.67B
AUM Growth
+$1.11B
Cap. Flow
+$178M
Cap. Flow %
2.05%
Top 10 Hldgs %
55.18%
Holding
87
New
9
Increased
9
Reduced
14
Closed
6

Top Buys

Rank Stock Value
1
BCAX
Bicara Therapeutics
BCAX
+$177M
2
ARTV
Artiva Biotherapeutics
ARTV
+$114M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$51.1M
4
BIOA
BioAge Labs
BIOA
+$44.3M
5
PCVX icon
Vaxcyte
PCVX
+$43.7M

Top Sells

Rank Stock Value
1
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$88.9M
2
VRNA
Verona Pharma
VRNA
+$64.6M
3
GERN icon
Geron
GERN
+$63.3M
4
ASND icon
Ascendis Pharma A/S
ASND
+$53.7M
5
URGN icon
UroGen Pharma
URGN
+$51.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.89%
2 Financials 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.5B
$1.45B 16.72%
9,710,428
-397,972
-4% -$53.7M
PCVX icon
2
Vaxcyte
PCVX
$7.65B
$993M 11.45%
8,689,190
+485,436
+6% +$43.7M
JANX icon
3
Janux Therapeutics
JANX
$912M
$416M 4.8%
9,165,652
– –
LEGN icon
4
Legend Biotech
LEGN
$3.65B
$366M 4.22%
7,506,934
– –
RYTM icon
5
Rhythm Pharmaceuticals
RYTM
$7.31B
$319M 3.68%
6,084,412
– –
RNAM
6
DELISTED
Avidity Biosciences
RNAM
$289M 3.34%
6,300,408
+900,000
+17% +$39.1M
TYRA icon
7
Tyra Biosciences
TYRA
$1.85B
$245M 2.82%
10,416,609
– –
EVH icon
8
Evolent Health
EVH
$371M
$241M 2.78%
8,514,862
– –
EWTX icon
9
Edgewise Therapeutics
EWTX
$4.28B
$238M 2.74%
8,909,091
– –
BIIB icon
10
Biogen
BIIB
$30.9B
$230M 2.65%
1,184,456
+202,317
+21% +$42.3M
DYN icon
11
Dyne Therapeutics
DYN
$4.68B
$229M 2.64%
6,381,144
+331,940
+5% +$13.2M
RXST icon
12
RxSight
RXST
$254M
$194M 2.23%
3,916,825
+222,000
+6% +$11.4M
BCAX
13
Bicara Therapeutics
BCAX
$1.7B
$177M 2.04%
+6,955,993
New +$177M
CLYM
14
Climb Bio
CLYM
$693M
$160M 1.84%
31,419,267
– –
SPRY icon
15
ARS Pharmaceuticals
SPRY
$579M
$157M 1.82%
10,860,977
– –
ACLX
16
DELISTED
Arcellx
ACLX
$155M 1.78%
1,851,479
+247,465
+15% +$16.5M
ARTV
17
Artiva Biotherapeutics
ARTV
$487M
$152M 1.76%
+9,853,302
New +$114M
WVE icon
18
Wave Life Sciences
WVE
$1.12B
$149M 1.72%
18,202,009
– –
GERN icon
19
Geron
GERN
$898M
$147M 1.69%
32,285,755
-13,916,670
-30% -$63.3M
VRNA
20
DELISTED
Verona Pharma
VRNA
$144M 1.66%
5,009,653
-2,622,993
-34% -$64.6M
NAMS icon
21
NewAmsterdam Pharma
NAMS
$3.26B
$134M 1.54%
8,064,000
– –
APGE icon
22
Apogee Therapeutics
APGE
$10.1B
$115M 1.33%
1,961,863
– –
DAWN
23
DELISTED
Day One Biopharmaceuticals
DAWN
$110M 1.26%
7,871,721
– –
ETNB
24
DELISTED
89bio
ETNB
$105M 1.21%
14,175,398
– –
RXRX icon
25
Recursion Pharmaceuticals
RXRX
$1.58B
$101M 1.17%
15,384,615
– –
1
2 3 4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, RA Capital Management held 87 positions worth $8.67B, up 15% from $7.56B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

RA Capital Management's Q3 2024 filing shows 9 new, 9 increased, 14 reduced and 6 closed positions. Its largest new stake was Bicara Therapeutics: 6,955,993 shares worth $177M. The largest sale was Longboard Pharmaceuticals, Inc. Common Stock, an estimated $88.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • RA Capital Management's largest Q3 2024 buy was Bicara Therapeutics: 6,955,993 shares worth $177M.
  • RA Capital Management added most to Vaxcyte in Q3 2024, an estimated $43.7M increase.
  • RA Capital Management's biggest Q3 2024 reduction was Verona Pharma, cutting an estimated $64.6M.
  • RA Capital Management fully exited Longboard Pharmaceuticals, Inc. Common Stock in Q3 2024, selling an estimated $88.9M.
  • RA Capital Management's ten largest holdings make up 55% of its $8.67B portfolio in Q3 2024.
  • RA Capital Management opened 9 new positions and closed 6 in Q3 2024.
  • RA Capital Management's portfolio value rose 15% quarter-over-quarter to $8.67B.

Based on RA Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.